Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Groupe la Francaise

Groupe la Francaise trimmed its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 86.4% in the 1st quarter, Holdings Channel reports. The firm owned 442 shares of the biopharmaceutical company’s stock after selling 2,806 shares during the period. Groupe la Francaise’s holdings in Regeneron Pharmaceuticals were worth $342,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Western Wealth Management LLC acquired a new stake in Regeneron Pharmaceuticals during the 1st quarter worth $26,000. Bank of America Corp DE raised its position in shares of Regeneron Pharmaceuticals by 2.8% in the first quarter. Bank of America Corp DE now owns 1,189,584 shares of the biopharmaceutical company’s stock valued at $919,120,000 after buying an additional 32,158 shares during the last quarter. Janus Henderson Group PLC raised its position in shares of Regeneron Pharmaceuticals by 1.7% in the first quarter. Janus Henderson Group PLC now owns 209,248 shares of the biopharmaceutical company’s stock valued at $161,637,000 after buying an additional 3,576 shares during the last quarter. Bull Harbor Capital LLC purchased a new position in shares of Regeneron Pharmaceuticals in the first quarter worth about $1,596,000. Finally, Ashton Thomas Securities LLC lifted its stake in shares of Regeneron Pharmaceuticals by 3.7% in the first quarter. Ashton Thomas Securities LLC now owns 1,259 shares of the biopharmaceutical company’s stock worth $973,000 after buying an additional 45 shares in the last quarter. 83.31% of the stock is owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals News Summary

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Q2 results substantially exceeded expectations. Regeneron reported non-GAAP EPS of $14.29 versus the $10.16 consensus and revenue of $4.29 billion versus estimates of $3.82 billion. Revenue rose 16.7% year over year. Growth was led by record Dupixent sales, which increased 38%, and U.S. EYLEA HD sales, which jumped 52% to $596 million. Regeneron Q2 2026 Results
• Positive Sentiment: Several analysts raised their price targets after the report. Cantor Fitzgerald lifted its target to $795 and maintained an overweight rating, while Truist raised its target to $772 and reiterated buy. These targets imply additional upside based on the referenced current price. Analyst Price Target Updates
• Neutral Sentiment: Analyst sentiment remains mixed. Morgan Stanley raised its target to $758 and RBC to $737, but both maintained equal-weight or sector-perform ratings. Wells Fargo also raised its target to $750 while keeping an equal-weight rating, suggesting limited conviction despite the earnings beat. Analyst Price Target Updates
• Neutral Sentiment: Regeneron declared a quarterly dividend of $0.94 per share, payable August 31 to shareholders of record August 18. The approximately 0.5% yield is modest and is unlikely to be a major stock catalyst.
• Negative Sentiment: Multiple law firms publicized a securities class action against Regeneron and its executives. The litigation alleges investors were misled about the protocol and prospects of the Phase 3 fianlimab-Libtayo melanoma trial, which ultimately failed and was associated with an approximately $11 billion market-cap loss. The September 14, 2026 lead-plaintiff deadline and continuing legal notices could pressure sentiment and create potential financial and reputational risks. Regeneron Securities Class Action

Insider Activity at Regeneron Pharmaceuticals

In other news, Director Arthur F. Ryan sold 200 shares of the company’s stock in a transaction on Thursday, July 2nd. The stock was sold at an average price of $650.15, for a total value of $130,030.00. Following the transaction, the director owned 17,303 shares of the company’s stock, valued at $11,249,545.45. This represents a 1.14% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.97% of the stock is currently owned by company insiders.

Regeneron Pharmaceuticals Trading Up 3.3%

Shares of REGN opened at $762.63 on Friday. The firm has a 50-day moving average price of $643.13 and a 200 day moving average price of $711.70. Regeneron Pharmaceuticals, Inc. has a 12-month low of $541.00 and a 12-month high of $821.11. The company has a current ratio of 4.29, a quick ratio of 2.96 and a debt-to-equity ratio of 0.09. The firm has a market capitalization of $80.63 billion, a P/E ratio of 18.85, a P/E/G ratio of 30.47 and a beta of 0.24.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 EPS for the quarter, beating the consensus estimate of $10.16 by $4.13. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The firm had revenue of $4.29 billion for the quarter, compared to analyst estimates of $3.82 billion. During the same quarter in the previous year, the company earned $12.81 EPS. The business’s revenue for the quarter was up 16.7% compared to the same quarter last year. Sell-side analysts forecast that Regeneron Pharmaceuticals, Inc. will post 2.06 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, August 31st. Shareholders of record on Tuesday, August 18th will be given a $0.94 dividend. The ex-dividend date is Tuesday, August 18th. This represents a $3.76 dividend on an annualized basis and a yield of 0.5%. Regeneron Pharmaceuticals’s payout ratio is currently 9.29%.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on REGN. Truist Financial upped their price objective on shares of Regeneron Pharmaceuticals from $769.00 to $772.00 and gave the company a “buy” rating in a research note on Friday. Citigroup lowered shares of Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and decreased their target price for the stock from $900.00 to $700.00 in a research note on Monday, May 18th. TD Cowen boosted their target price on Regeneron Pharmaceuticals from $880.00 to $960.00 and gave the stock a “buy” rating in a report on Thursday, April 23rd. Guggenheim upped their price target on Regeneron Pharmaceuticals from $995.00 to $1,000.00 and gave the company a “buy” rating in a research report on Tuesday, July 21st. Finally, BMO Capital Markets cut their price target on Regeneron Pharmaceuticals from $900.00 to $730.00 and set an “outperform” rating for the company in a report on Monday, May 18th. One analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and nine have issued a Hold rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $794.83.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.